These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9598506)

  • 1. Calculating prostate cancer volume preoperatively: the D'Amico equation and some other observations.
    Chan LW; Stamey TA
    J Urol; 1998 Jun; 159(6):1998-2003. PubMed ID: 9598506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
    Stamey TA; Yemoto CM; McNeal JE; Sigal BM; Johnstone IM
    J Urol; 2000 Apr; 163(4):1155-60. PubMed ID: 10737486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative PSA is still predictive of cancer volume and grade in late PSA era.
    Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA
    Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
    Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
    J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
    Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
    J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens.
    Pettaway CA; Troncoso P; Ramirez EI; Johnston DA; Steelhammer L; Babaian RJ
    J Urol; 1998 Aug; 160(2):437-42. PubMed ID: 9679893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.
    Noldus J; Stamey TA
    J Urol; 1996 Jan; 155(1):232-7. PubMed ID: 7490842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.
    Noldus J; Graefen M; Huland E; Busch C; Hammerer P; Huland H
    J Urol; 1998 Jun; 159(6):2004-7; discussion 2007-8. PubMed ID: 9598507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.